Current cancer immunotherapy using activated lymphocytes-do lymphocytes actually recognize cancer cells?

Yoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, Masahiro Yamamura, Akira Sawaki

Research output: Contribution to journalReview articlepeer-review

Abstract

Molecular cloning of interleukin-2 (IL-2) has enabled adoptive cell therapy (ACT) to be established by using autologous activated lymphocytes. The low of regenerative medicine will promote the active development of ACT for public use, and ACTs that utilize tumor-infiltrating lymphocytes (TIL), in vitro tumor-sensitized lymphocytes, natural killer T cells, and gammadelta T cells are being evaluated as advanced medical treatments in Japan. In addition, chimeric antigen receptor gene-modified T (CAR-T) cells and T cell receptor gene-modified T (TCR-T) cells are available for investigational clinical use. CART and TCR-T cells have been associated with serious adverse events as well as drastic clinical efficacies, indicating the importance of choosing the antigens to be targeted. Presently, it is accurate to state that lymphocytes do recognize cancer cells. Clinical ACT research focusing on TIL and mutated cancer antigens will be initiated for the development of personalized immunotherapy for cancer in the future.

Original languageEnglish
Pages (from-to)1031-1035
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume42
Issue number9
Publication statusPublished - 09-2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Current cancer immunotherapy using activated lymphocytes-do lymphocytes actually recognize cancer cells?'. Together they form a unique fingerprint.

Cite this